Dimerix Limited announced that patients from the current phase 2 trials will continue treatment with DMX-200 via the Therapeutic Goods Association's (TGA) compassionate use Special Access Scheme (SAS) following completion of the study protocol and recommendation by their physicians. These patients are in addition to previously reported SAS patients from the phase 2 trial completed in 2017 who also continue to be treated with DMX 200 via the TGA's SAS. The TGA approved the SAS Category B applications based on the safety profile of DMX-200, as well as clinical evidence that DMX-200 may benefit patients. Dimerix will facilitate continued access to DMX-200 via the physician through the Special Access Scheme at the physician's request.